

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-7. (Canceled)

8. (Previously presented) The external patch according to claim 10 or 11, wherein the flexible film is low density polyethylene film.

9. (Previously presented) The external patch according to claim 10 or 11, wherein the acrylic component of the acrylic pressure-sensitive adhesive is selected from least one of the following compounds: 2-ethylhexyl acrylate, acrylic acid, ethyl acrylate, vinyl acetate, and an acrylic ester.

10. (Previously presented) An external patch comprising a backing and a pressure-sensitive adhesive layer, wherein the backing is a laminate structure comprising a flexible film as an outer layer and a drug non-adsorptive layer, wherein said flexible film has a thickness of 1 to 200 $\mu$ m and is selected from at least one of the group consisting of woven fabrics, non-woven fabrics and polymer films; wherein said drug non-adsorptive layer has a thickness of 0.1 to 10 $\mu$ m and is a polyethylene terephthalate film; and wherein said pressure-sensitive adhesive layer is made of an acrylic pressure-sensitive adhesive, said pressure-sensitive adhesive layer being adjacent to said drug non-adsorptive layer and not adjacent to the flexible film, wherein the adhesive layer comprises:

0.01 to 1% by weight of an isocyanate-based crosslinking agent;

0.5 to 10% by weight of estradiol and/or a derivative of estradiol as an active ingredient;

0.5 to 10% by weight of crotamiton; and

0.1 to 10% by weight of oleic acid.

11. (Previously presented) An external patch comprising a backing and a pressure-sensitive adhesive layer, wherein the backing is a laminate structure comprising a flexible film as an outer layer and a drug non-adsorptive layer, wherein said flexible film has a thickness of 1 to 200µm and is selected from at least one of the group consisting of woven fabrics, non-woven fabrics and polymer films; wherein said drug non-adsorptive layer has a thickness of 0.1 to 10µm and is a polyethylene terephthalate film, said pressure-sensitive adhesive layer being adjacent to said drug non-adsorptive layer and not adjacent to the flexible film; and wherein said pressure-sensitive adhesive layer is made of an acrylic pressure-sensitive adhesive, wherein the adhesive layer comprises:

- 0.01 to 1% by weight of an isocyanate-based crosslinking agent;
- 1 to 30% by weight of isopropyl myristate as a distribution coefficient control agent; and
- 0.5 to 10% by weight of norethisterone and/or a derivative of nonethisterone as an active ingredient.

12. (Currently amended) An external patch comprising a backing and a pressure-sensitive adhesive layer, wherein the backing is a laminate structure comprising a low density polyethylene flexible film as an outer layer having a thickness of 1 to 200µm and a drug non-adsorptive layer, wherein said drug non-adsorptive layer has a thickness of 0.1 to 10µm and is a polyethylene terephthalate film; and wherein said pressure-sensitive adhesive layer is made of an acrylic pressure-sensitive adhesive, said pressure-sensitive adhesive layer being adjacent to said drug non-adsorptive layer and not adjacent to the flexible film, wherein the adhesive layer consists of:

- 0.01 to 1% by weight of an isocyanate-based crosslinking agent;
- 0.5 to 10% by weight of estradiol and/or a derivative of estradiol as an active ingredient;
- 0.5 to 10% by weight of crotamiton; and
- 0.1 to 10% by weight of oleic acid.

13. (Currently amended) An external patch comprising a backing and a pressure-sensitive adhesive layer, wherein the backing is a laminate structure comprising a low density polyethylene flexible film as an outer layer having a thickness of 1 to 200µm and a drug non-adsorptive layer, wherein said drug non-adsorptive layer has a thickness of 0.1 to 10µm and is a polyethylene terephthalate film, and wherein said pressure-sensitive adhesive layer being adjacent to said drug non-adsorptive layer and not adjacent to the flexible film; and wherein said pressure-sensitive adhesive layer is made of an acrylic pressure-sensitive adhesive, wherein the adhesive layer consists of:

0.01 to 1% by weight of an isocyanate-based crosslinking agent;

1 to 30% by weight of isopropyl myristate as a distribution coefficient control agent; and

0.5 to 10% by weight of norethisterone and/or a derivative of nonethisterone as an active ingredient.

14. (Currently amended) An external patch for application to a skin surface consisting of:

a) a low density polyethylene flexible film as an outermost layer, which is oriented farthest from the skin surface when applied to the skin surface, wherein said flexible film has a thickness of 1 to 200µm;

b) a drug non-adsorptive as a layer adjacent to the flexible film layer, wherein said drug non-adsorptive layer has a thickness of 0.1 to 10µm and is a polyethylene terephthalate film;

c) a pressure-sensitive adhesive layer adjacent to the drug non-adsorptive layer and not adjacent to the flexible film, wherein the adhesive layer consists of

0.01 to 1% by weight of an isocyanate-based crosslinking agent,

0.5 to 10% by weight of estradiol and/or a derivative of estradiol as an active ingredient,

0.5 to 10% by weight of crotamiton, and

0.1 to 10% by weight of oleic acid; and

d) a release layer adjacent to the pressure-sensitive adhesive layer and next to the skin surface when applied to the skin surface.

15. (Currently amended) An external patch for application to a skin surface consisting of :

a) a low density polyethylene flexible film as an outermost layer, which is oriented farthest from the skin surface when applied to the skin surface, wherein said flexible film has a thickness of 1 to 200µm;

b) a drug non-adsorptive as a layer adjacent to the flexible film layer, wherein said drug non-adsorptive layer has a thickness of 0.1 to 10µm and is a polyethylene terephthalate film;

c) a pressure-sensitive adhesive layer adjacent to the drug non-adsorptive layer and not adjacent to the flexible film, wherein the adhesive layer consists of

0.01 to 1% by weight of an isocyanate-based crosslinking agent;

1 to 30% by weight of isopropyl myristate as a distribution coefficient control agent, and

0.5 to 10% by weight of norethisterone and/or a derivative of nonethisterone as an active ingredient; and

d) a release layer adjacent to the pressure-sensitive adhesive layer and next to the skin surface when applied to the skin surface.